Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Zist Daru, ZIFERON
Viral triggers of multiple sclerosis.
The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system.
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls.
MS Research Roundup: May 16, 2014
Positive results from Phase 3 CONFIRM clinical trial show efficacy and safety of oral BG-12 in multiple sclerosis
Mycophenolate mofetil in the treatment of multiple sclerosis: A preliminary report.
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity.
XVI European Charcot Foundation lecture: nutrition and environment, can MS be prevented?
Episode 42 with Dr. Lawrence Steinman on amyloid in experimental autoimmune encephalomyelitis
Episode 37 with Dr. Jeanne Loring on human pluripotent stem cells in a mouse model of MS
MS Research Roundup: July 18, 2014
[Recommendations for a brief international cognitive assessment for multiple sclerosis].
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.
Episode 49 with Dr. Hugh Rosen on sphingosine 1-phosphate receptor modulators
EMD Serono Joins ACP to Launch OPT-UP Study
Mycophenolate mofetil therapy in the management of inflammatory bowel disease - A retrospective case series and review.
Seeing illness in art and medicine: a patient and printmaker collaboration.
Episode 61 with Dr. Yanming Wang on molecular imaging of the myelin sheathing of axons
Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.
TECFIDERA® (dimethyl fumarate) approved in the European Union as a first-line oral treatment for multiple sclerosis
SMC Says Yes to Aubagio® (teriflunomide), a New Once Daily First-line Oral Treatment Available for People with an Active Relapsing Remitting Form of MS

Pages